These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 20973926)

  • 21. Anemia in renal disease: diagnosis and management.
    Lankhorst CE; Wish JB
    Blood Rev; 2010 Jan; 24(1):39-47. PubMed ID: 19833421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in heart failure patients: A protocol for systematic review and meta-analysis.
    Fukuta H; Hagiwara H; Kamiya T
    PLoS One; 2022; 17(9):e0275311. PubMed ID: 36170343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic kidney disease-associated anemia: new remedies.
    Del Vecchio L; Cavalli A; Tucci B; Locatelli F
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1030-8. PubMed ID: 20730698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recognition and treatment of anemia in the setting of heart failure due to systolic left ventricular dysfunction.
    Howlett JG
    Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):199-208. PubMed ID: 18248274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse consequences with use of erythropoiesis-stimulating agents in anemia prompt release of guidelines to ensure safe use and maximize benefit.
    Dharmarajan TS; Widjaja D
    Geriatrics; 2008 Jun; 63(6):13-29. PubMed ID: 18512996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erythropoietin and chronic lymphocytic leukemia.
    Mauro FR; Gentile M; Foa R
    Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
    Singh AK
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging role of anemia in heart failure.
    Mitchell JE
    Am J Cardiol; 2007 Mar; 99(6B):15D-20D. PubMed ID: 17378990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythropoiesis stimulating agents (ESAs) for congestive heart failure: the red and the black.
    Robles NR; Macias JF; Herrera J
    Eur J Intern Med; 2014 Feb; 25(2):193-6. PubMed ID: 24491240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of erythropoietin in anemia after heart transplantation.
    Gleissner CA; Klingenberg R; Staritz P; Koch A; Ehlermann P; Wiggenhauser A; Dengler TJ
    Int J Cardiol; 2006 Oct; 112(3):341-7. PubMed ID: 16309765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erythropoietic stimulating agents.
    Testa U
    Expert Opin Emerg Drugs; 2010 Mar; 15(1):119-38. PubMed ID: 20158404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anemia in heart failure:current evidence and challenges.
    Tang WH
    Rev Cardiovasc Med; 2007; 8(2):78-86. PubMed ID: 17603426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anaemia in older people with chronic heart failure: The potential cost.
    Man-Fai Sim V; Nam MC; Riley S; Yousef Z; Hurley J; Cheung WY; O'Mahony S
    Technol Health Care; 2009; 17(5-6):377-85. PubMed ID: 20051617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia.
    Beck-da-Silva L; Rohde LE; Pereira-Barretto AC; de Albuquerque D; Bocchi E; Vilas-Boas F; Moura LZ; Montera MW; Rassi S; Clausell N
    J Card Fail; 2007 Feb; 13(1):14-7. PubMed ID: 17338998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anemia and heart failure.
    Ghali JK
    Curr Opin Cardiol; 2009 Mar; 24(2):172-8. PubMed ID: 19532104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triumph and tragedy: anemia management in chronic kidney disease.
    Novak JE; Szczech LA
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erythropoiesis-stimulating agents in anemia: use and misuse.
    Dharmarajan TS; Widjaja D
    J Am Med Dir Assoc; 2009 Nov; 10(9):607-16. PubMed ID: 19883882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron?
    Silverberg DS; Wexler D; Iaina A
    J Nephrol; 2004; 17(6):749-61. PubMed ID: 15593047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
    Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
    Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.